/Investor DB

Frazier Healthcare Partners — 2025 Investments

5 investments dated 2025 · listed companies and verified rows first · show all

Alestaalestatherapeutics.cominSeries A · Jan 2025 · $67M

Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.

BiotechHealthtech

Ilan Ganot(CEO)inBenit Maru(CMO)Matthias Van Woensel(CSO)in

Co-investorsDroia VenturesFrazier Life SciencesNovartis Venture FundRV Invest GmbHMPM BioImpactRTW Investments L.P.+1 more

Hillstar Biohillstarbio.cominSeries A · Mar 2025 · $67M

Hillstar Bio develops precision immunotherapies for autoimmune diseases, using antibody engineering to selectively deplete pathogenic immune cells while sparing healthy ones.

BiotechHealthtech

Co-investorsDroia VenturesFrazier Life SciencesLifeArc Ventures

Iolyxiolyx.cominSeries B · Dec 2025 · $15M

Iolyx is a pharmaceutical company focused on developing treatments for ocular conditions.

BiotechMedical Devices

Elizabeth Jeffords(CEO & President)inErin Newman(Chief Development Officer)inShannon Dahl(Chief Scientific Officer)inBryan Boyle(Chief Legal & Administrative Officer)in

Co-investorsAlumni VenturesFrazier Life Sciences

Tubulis GmbHtubulis.comin𝕏Series C · Oct 2025 · $400Macquired by Gilead Sciences

Tubulis develops antibody-drug conjugates (ADCs) for cancer treatment, using proprietary conjugation platform technologies to create tumor-targeting therapeutics.

BiotechDeep TechMedical DevicesPlanegg-Martinsried, DE

Dominik Schumacher(Co-founder & CEO)inJonas Helma-Smets(Co-founder & Chief Scientific Officer)Christian Hackenberger(Scientific Co-founder)

Co-investorsAndera PartnersBioMedPartnersEQT Life SciencesNexTech VenturesAscenta CapitalBayern Kapital+7 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Callio Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.